All Clinical Trials in Canada

A listing of 3905 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

Canada

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Bayis Ilh Tus - A Strong Breath: Prevalence and Contributors to COPD in First Nations Communities in British Columbia

NCT04105088

Recruiting

Background. First Nations peoples in Canada carry an increased respiratory health burden compared to non-First Nations. However, there is little accurate information of how many First Nations people have COPD, especially in remote and rural areas. Goal \& Aims of the Study. The goal of this study is to estimate the burden of COPD in remote and rural First Nations communities. This project is a partnership between the University of British Columbia (UBC), Carrier Sekani Family Services (CSFS), a... Read More

Gender:

ALL

Ages:

30 years and above

Trial Updated:

01/18/2024

Locations: 13 individual First Nations in north-Central BC near Prince George, BC, Prince George, British Columbia

Conditions: Pulmonary Disease, Chronic Obstructive

Learn More ›

DECT for Differentiating Intracerebral Hemorrhage From Contrast Extravasation

NCT05675774

Recruiting

The goal of this clinical trial is to investigate the use of DECT (Dual-Energy Computed Tomography) in patients with acute ischemic stroke who receive an intervention (thrombolysis or thrombectomy). The main questions to answer are: 1. Can DECT more accurately differentiate hyperdensities as intracranial haemorrhage (ICH) or contrast extravasation compared with single-energy CT (SECT)?. 2. Will DECT lead to better care for patients with AIS who receive intervention and have post-procedural hype... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/17/2024

Locations: Health Sciences Center, Winnipeg, Manitoba

Conditions: Stroke, Ischemic, Tomography, X-Ray Computed

Learn More ›

Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab

NCT05694884

Recruiting

Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/17/2024

Locations: ASLAN Investigative Site, Birmingham, Alabama +26 locations

ASLAN Investigative Site, Birmingham, Alabama

ASLAN Investigative Site, Encino, California

ASLAN Investigative Site, Fountain Valley, California

ASLAN Investigative Site, Long Beach, California

ASLAN Investigative Site, Los Angeles, California

ASLAN Investigative Site, Sherman Oaks, California

ASLAN Investigative Site, Boca Raton, Florida

ASLAN Investigative Site, Hollywood, Florida

ASLAN Investigative Site, Miami Lakes, Florida

ASLAN Investigative Site, North Miami Beach, Florida

ASLAN Investigative Site, Orange City, Florida

ASLAN Investigative Site, Saint Augustine, Florida

ASLAN Investigative Site, Saint Petersburg, Florida

ASLAN Investigative Site, New Albany, Indiana

ASLAN Investigative Site, Louisville, Kentucky

ASLAN Investigative Site, Quincy, Massachusetts

ASLAN Investigative Site, Auburn Hills, Michigan

ASLAN Investigative Site, Las Vegas, Nevada

ASLAN Investigative Site, E. Amherst, New York

ASLAN Investigative Site, Charlotte, North Carolina

ASLAN Investigative Site, Oklahoma City, Oklahoma

ASLAN Investigative Site, Johnston, Rhode Island

ASLAN Investigative Site, Charleston, South Carolina

ASLAN Investigative Site, Hamilton, Ontario

ASLAN Investigative Site, Ottawa, Ontario

ASLAN Investigative Site, Toronto, Ontario

Conditions: Atopic Dermatitis

Learn More ›

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

NCT05065021

Recruiting

The purpose of this research study is to see how useful it is to look at biomarkers in the blood and tumor tissue of participants with ovarian, fallopian tube or primary peritoneal cancer who have previously received treatment with a drug called a PARP inhibitor, and using the results to determine the best treatment for these participants. Biomarkers are molecules such as genes (molecules that contain instructions for the development and function of cells in the body) and proteins that may be us... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

01/14/2024

Locations: Princess Margaret Cancer Centre, Toronto, Ontario

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High Grade Serous Cancer, High Grade Endometrioid Cancer

Learn More ›

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

NCT01949129

Recruiting

The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication for HSCT with a myeloablative conditioning regimen. The stratification of patients in first and following remissions according to the individual transplan... Read More

Gender:

ALL

Ages:

Between 1 month and 18 years

Trial Updated:

01/12/2024

Locations: Hospital de Pediatria "Juan P. Garrahan" Combate de Los Pozos N°1800 CABA, Buenos Aires, Not set +118 locations

Hospital de Pediatria "Juan P. Garrahan" Combate de Los Pozos N°1800 CABA, Buenos Aires, Not set

Hospital Sor Maria Ludovica, Department Hematology Stem Cell Transplant Unit, La Plata, Not set

Children's Cancer Centre The Royal Children's Hospital, Melbourne, Not set

Princess Margaret Hospital for Children, Perth, Not set

Sydney Children's Hospital, Randwick, Not set

Lady Cilento Children's Hospital, South Brisbane, Not set

The Children's Hospital at Westmead Oncology Unit, Sydney, Not set

Universitätsklinik für Kinder- und Jugendheilkunde, Abt. f. Hämato-Onkologie, Graz, Not set

Universitätsklinik für Kinder- und Jugendheilkunde, Innsbruck, Not set

St. Anna Children's Hospital, Vienna, Austria, Vienna, Not set

Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Not set

Hôpital Universitaire des Enfants Reine Fabiola (HUDERF), Brussels, Not set

Cliniques Universitaires Saint-Luc (UCL) Hématologie et oncologie pédiatrique, Brussels, Not set

University Hospital Gent Pediatrische hemato-oncologie, Gent, Not set

University Hospitals Leuven Kinderhemato-oncologie, Leuven, Not set

Centre Hospitalier Universitaire de Liège Domaine Universitaire du Sart Tilman, Liège, Not set

Alberta Children's Hospital Division of Pediatric Oncology, Calgary, Not set

Montreal Children's Hospital, Montral, Not set

CHU Sainte-Justine Hematology-Oncology Division, Montreal, Not set

Hospital for Sick Children University of Toronto Division of Haematology/Oncology, Toronto, Not set

BC Children's Hospital, Vancouver, Not set

CancerCare Manitoba/University of Manitoba, Winnipeg, Not set

Hospital Dr Luis Calvo Mackenna, Santiago, Not set

Department of Pediatrics, UHC Zagreb, Zagreb, Not set

Department of Pediatric Hematology and Oncology Teaching Hospital Motol, 2nd Medical School, Charles University, Prague, Not set

Paediatric Stem Cell Transplant and Immune Deficiency, Dept. for children and adolescents 4072, Rigshospitalet, Copenhagen, Not set

Division of Hematology-Oncology and Stem Cell Transplantation, Hospital for Children and Adolescents, Univ. of Helsinki, Helsinki, Not set

CHU Bordeaux, Bordeaux, Not set

CHU Clermont-Ferrand, Clermont-Ferrand, Not set

CHU Grenoble - Clinique Universitaire de Pédiatrie, Hôpital Couple Enfant, Grenoble, Not set

CHRU Lille, Service d'Hématologie Pédiatrique, Lille, Not set

IHOP / Lyon, Service Hématologie et d'Oncologie pédiatrique, Lyon, Not set

Hopital la Timone Adulte, Marseille, Not set

Hopital Arnaud de Villeneuve, Montpellier, Not set

CHU Nancy - Hopital d'Enfants, Nancy, Not set

CHU Nantes, Service d'onco hémato pédiatrie, Nantes, Not set

Hôpital Robert Debré, Paris, Not set

CHU de Rennes, Serive d'Onco-Pédiatrie, Rennes, Not set

CHU de Rouen, Hopital des Enfants, Service d' Immuno-Hématologie Oncologie Pédiatrique, Rouen, Not set

CHU Strasbourg, Service d'hématologie et d'oncologie pédiatrique, Strasbourg, Not set

Uniklinik RWTH Aachen, Kinder- und Jugendmedizin, Aachen, Not set

Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Not set

Universitätsklinikum Bonn, Abteilung für Pädiatrische Hämatologie und Onkologie, Bonn, Not set

Universitätsklinikum Düsseldorf, Klinik für Kinder-Onkologie, -Hämatologie und Klinische Immunologie, Düsseldorf, Not set

Universitätsklinikum Erlangen, Kinder- und Jugendklinik, Erlangen, Not set

Universitätsklinikum Essen, Klinik für Kinderheilkunde III, Essen, Not set

Klinikum der Johann Wolfgang Goethe-Universität, Klinik für Kinder- und Jugendmedizin (KKJM), Frankfurt am Main, Not set

Universitätsklinikum Freiburg, Zentrum für Kinder- und Jugendmedizin, Freiburg, Not set

Universitätsklinikum Gießen, Zentrum für Kinder- und Jugendmedizin, Gießen, Not set

Universitätsmedizin Greifswald, Klinik und Poliklinik für Kinder- und Jugendmedizin, Greifswald, Not set

Universitätsklinikum Halle (Saale), Universitätsklinik und Poliklinik für Kinder- und Jugendmedizin, Halle, Not set

Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Pädiatrische Hämatologie und Onkologie, Hamburg, Not set

Medizinische Hochschule Hannover, Zentrum Kinderheilkunde und Jugendmedizin, Hannover, Not set

Universitätsklinikum Heidelberg, Zentrum für Kinder- und Jugendmedizin, Heidelberg, Not set

Universitätsklinikum Jena, Sektion für Stammzelltransplantation, Jena, Not set

UKSH - Universitätsklinikum Schleswig-Holstein, Klinik für Allgemeine Pädiatrie, Kiel, Not set

Universitätsmedizin Leipzig, Abteilung für Pädiatrische Onkologie, Hämatologie und Hämostaseologie, Leipzig, Not set

Klinikum der Universität München, Dr. von Haunersches Kinderspital, München, Not set

Städt. Krankenhaus München Schwabing, Universitätskinderklinik der TU München, München, Not set

Universitätsklinikum Münster, Klinik für Kinder- und Jugendmedizin, Münster, Not set

Universitätsklinikum Regensburg, Klinik und Poliklinik für Kinder- und Jugendmedizin, Regensburg, Not set

Universitätsklinik für Kinder- und Jugendmedizin Tübingen, Tübingen, Not set

Universitätsklinikum Ulm, Klinik für Kinder- und Jugendmedizin, Ulm, Not set

Universitäts-Kinderklinik Würzburg, Würzburg, Not set

Saint Sophia Children's Hospital BMT Unit, Athens, Not set

National Institute of Haematology and Infectious Disease, Hospital of Southern Pest, Paediatric Bone Marrow Transplantation Unit, Budapest, Not set

Rambam Medical Center, Haifa, Not set

Schneider Children's Medical Center of Israel, Petach-Tikva, Not set

Dana Children's Hospital, Tel Aviv, Not set

Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi di Bologna, Bologna, Not set

Ospedale Mayer di Firenze SODc Tumori Pediatrici e TMO, Florence, Not set

Istituto Gaslini Genova Oncoematologia Pediatrica-, Genoa, Not set

A.O. San Gerardo di Monza Clinica Pediatrica, Monza, Not set

A.O.R.N. Santobono Pausilipon, Dipartimento di Oncoematologia, Napoli, Not set

Azienda Ospedaliera di Padova Oncoematologia Pediatrica, Padova, Not set

Fondazione IRCCS Policlinico San Matteo, Pavia, Not set

Azienda Ospedaliero Universitaria Pisana U.O. di Oncoematologia Pediatrica A.O., Pisa, Not set

Ospedale Pediatrico Bambino Gesù, Sapienza, University of Rome, Rome, Not set

Ospedale Infantile Regina Margherita SC Oncoematologia e Centro Trapianti, Torino, Not set

University of Malaya, Department of Paediatrics, Kuala Lumpur, Not set

Instituto Nacional de Peditria, Ciudad de México, Not set

Leiden University Medical Center Department of Pediatrics/BMT unit, Leiden, Not set

Princess Máxima Center for Pediatric Oncology, Utrecht, Not set

Starship Children's Hospital, Auckland, Not set

Oslo University Hospital Rikshospitalet, Oslo, Not set

University Hospital No.1, Collegium Medicum UMK, department of Paediatrics, Oncology, Hematology and Paediatric Transplantology, Bydgoszcz, Not set

University Children's Hospital in Krakow, Department of Transplantation, Kraków, Not set

Children's University Hospital, Dept. Pediatric Hematology, Oncology, and Transplantology, Lublin, Not set

Poznan University of Medical Sciences, Department of Pediatric Onology, Hematology & HSCT, Poznań, Not set

Cape of Hope, Wroclaw Medical University, Wrocław, Not set

IInsitutul Clinic Fundeni, Sectia de Transplant Medular, Bukarest, Not set

University of Medicine and Pharmacy V. BABES, Emergency Children's Hospital LOUIS TURCANU, III. Clinic of Pediatrics , Department of Onco-hematology and Bone Marrow Transplantation, Timişoara, Not set

King Abdullah specialists children hospital, Riyadh, Not set

University Children's Hospital, Bratislava, Not set

University childrens' hospital, UMCL, Ljubljana, Not set

Hospital Santa Creu i Sant Pau, Barcelona, Not set

Hospital Vall d'Hebron, Barcelona, Not set

Hospital Virgen de la Arrixaca, Murcia, Not set

Hospital Materno Infantil de Málaga, Málaga, Not set

Hospital Universitario Central de Asturias, Oviedo, Not set

Queen Silvia Children's Hospital, Department of Pediatric Oncology (Avdelnig 321-322), Göteborg, Not set

Skane University Hospital, Dept. of Pediatrics, Section for Hematology and Oncology, Lund, Not set

Karolinska University Hospital, Department of Pediatrics, Stockholm, Not set

University Children's Hospital, Dept. of Women's & Children's Health Section for Pediatrics, Uppsala, Not set

Universitäts-Kinderspital beider Basel (UKBB), Basel, Not set

HUG Hôpitaux Universitaire de Genève, Geneva, Not set

Universitäts-Kinderspital Zurich, Zurich, Not set

Ankara University School of Medicine Pediatric Stem Cell Transplantation Unit, Ankara, Not set

Gazi University School of Medicine Pediatric Stem Cell Transplantation Unit, Ankara, Not set

Gülhane Training and Research Hospital, Ankara, Not set

Akdeniz University School of Medicine Pediatric Stem Cell Transplantation Unit, Antalya, Not set

Bahcesehir University School of Medicine Pediatric Stem Cell Transplantation Unit, Antalya, Not set

Acibadem University Atakent Hospital Pediatric Stem Cell Transplantation Unit, Istanbul, Not set

Bahcelievler Medicalpark Hospital Pediatric Stem Cell Transplantation Unit, Istanbul, Not set

Bahcesehir University School of Medicine Pediatric Stem Cell Transplantation Unit, Istanbul, Not set

Medipol Mega Üniversite Hastanesi, Istanbul, Not set

Dokuzeylul University School of Medicine Pediatric Stem Cell Transplantation Unit, Izmir, Not set

Ege University School of Medicine Pediatric Stem Cell Transplantation Unit, Izmir, Not set

Erciyes University School of Medicine Pediatric Stem Cell Transplantation Unit, Kayseri, Not set

Conditions: Acute Lymphoblastic Leukaemia

Learn More ›

The Effect of In-utero Exposure to Metformin in 5-11 Year Old Offspring of Mothers in the MiTy Trial

NCT05025852

Recruiting

The incidence of diabetes in pregnancy is rising, with rates of 1 in 7 pregnancies globally. Metformin is used for type 2 diabetes (T2DM) outside of pregnancy and is now increasingly prescribed during pregnancy. There are some concerns as metformin crosses the placenta and effects on offspring exposed during pregnancy are unknown. Animal and human evidence indicate that metformin may create an atypical in-utero environment similar to under-nutrition which has been associated with adult obesity. This is supported by studies in children of mothers treated with metformin in other populations where an increase in childhood obesity was found at 4-9 years of age. We now have evidence from the MiTy trial, that offspring of metformin-exposed women with T2DM have less large infants and are less adipose at birth, but are also more likely to be small for gestational age (SGA). These effects could lead to benefit or harm in the long-term. Offspring of MiTy mothers are currently being followed up to 2 years. Given that long-term effects may not be evident until 5 years of age, it is imperative to follow these children longer. Goals/Research Aims:To determine whether in-utero exposure to metformin, in offspring of women with T2DM, is beneficial or harmful in the long-term. Research Questions: 1. In offspring of women with T2DM, how does treatment with metformin during pregnancy affect a) adiposity b) growth over time c) metabolic syndrome d) cognitive and behavioral measures:2. What factors predict altered childhood adiposity and insulin resistance in these offspring? Primary Outcome: Body mass index (BMI) z-score. Secondary Outcomes: 1) other measures of adiposity (i.e. skinfolds, 2) growth over time 3) measures of insulin resistance 4) adipocytokines 5)neurodevelopment Expected Outcomes Given these increasing concerns, this study will inform the best treatment for pregnant mothers with diabetes by studying the long-term outcomes of children exposed to metformin during pregnancy. Read Less

Gender:

ALL

Ages:

All

Trial Updated:

01/11/2024

Locations: Campbelltown Hospital, Campbelltown, New South Wales +11 locations

Conditions: Diabetes Mellitus, Type 2, Pregnancy in Diabetic, Child Obesity, Child Development

Learn More ›

Redesigning the Surgical Pathway (PROMoTE)

NCT05114876

Recruiting

Cognitive complications, that is problems with thinking and memory, are incredibly common after surgery, occurring in 10-50% of all older surgical patients. These complications can take different forms, but one of the most common is postoperative delirium (POD), a short-term state of confusion. In addition to being stressful for patients and their families, POD is linked to longer hospital stays, increased costs, higher mortality rates and other problems after surgery. Despite this, POD is often... Read More

Gender:

ALL

Ages:

60 years and above

Trial Updated:

01/11/2024

Locations: Sunnybrook Health Sciences Centre, Toronto, Ontario

Conditions: Delirium, Cognitive Impairment, Perioperative/Postoperative Complications, Cognitive Dysfunction, Cognitive Decline

Learn More ›

Over-the-Counter Antihistamines & Heat Stress

NCT06217367

Recruiting

Allergic rhinitis (AR) currently affects \~25% of Canadians, and due to factors of climate change, this number is expected to increase over the coming decade. AR symptoms can significantly impact individuals' quality of life by compromising sleep, productivity, and social interactions. To alleviate AR symptoms, North Americans tend to rely on H1 antihistamine medications available over-the-counter (OTC) at most pharmacies. However, public health authorities currently suggest restraining all anti... Read More

Gender:

ALL

Ages:

Between 19 years and 39 years

Trial Updated:

01/11/2024

Locations: Lakehead University C.J Sanders Fieldhouse, Thunder Bay, Ontario

Conditions: Heat Illness, Allergic Rhinitis, Heat Injury, Sudomotor Sympathetic Dysfunction

Learn More ›

Investigating the Use of Goal Management Therapy in Improving Cognitive Functioning in Public Safety Personnel With PTSD

NCT04251624

Recruiting

This study examines the efficacy of Goal Management Therapy (GMT) - a well-established cognitive remediation strategy aimed at improving goal-directed behaviors that are dependent on basic cognitive processes and on executive functioning - among public safety personnel with post-traumatic stress disorder.

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

01/10/2024

Locations: Homewood Research Institute, Guelph, Ontario

Conditions: Post Traumatic Stress Disorder, Cognitive Deficit

Learn More ›

Conventional-therapy & FES-therapy In-Veritas Effects Study

NCT05247450

Recruiting

This randomized clinical trial will primarily compare the effectiveness of conventional physiotherapy alone with combined conventional physiotherapy and FES-t along with task-specific training in terms of the improvement of the functional and neurological recovery of patients with persistent C5 palsy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/10/2024

Locations: KITE Toronto Research Institute, Toronto, Ontario

Conditions: C5 Palsy

Learn More ›

Using Thermography to Assess the Affects of Sildenafil Cream, 3.6%

NCT05765487

Recruiting

The goal of this clinical trial is to compare thermography images in normal healthy premenopausal women after the application of Sildenafil Cream, 3.6%, L-arginine cream, and placebo cream. Participants will be shown a series of explicit videos to elicit a change in genital temperature before and after application of cream.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

01/09/2024

Locations: Pharma Medica Research, Inc., Mississauga, Ontario

Conditions: Sexual Arousal Disorder

Learn More ›

The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial

NCT03447938

Recruiting

MICS CABG (Minimally invasive coronary surgery), where coronary artery bypass grafting (CABG) is completed through a small incision over the left chest, has evolved to become a safe and less invasive alternative to conventional sternotomy CABG. Several observational studies have suggested significantly shorter time to return to physical activity for MICS CABG patients compared to sternotomy CABG patients. A randomized study is warranted to validate these findings, provide higher level of evidenc... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/08/2024

Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania +12 locations

Conditions: Coronary Artery Disease

Learn More ›